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Cutaneous clear cell sarcoma (CCS) is a rare soft tissue malignancy that typically manifests in the distal
extremities of young adults. Although it shows melanocytic differentiation, CCS is clearly pathologically
and genetically distinct from malignant melanoma. Here, we report the case of a 43-year-old male who
had an asymptomatic, deep-seated, slowly enlarging, ﬁrm mass over the right heel for 30 years that
recently and rapidly progressed with tenderness. We arranged for the total excision of the tumor.
Pathological and cytogenetic analysis of the biopsied specimen showed that it was a clear cell sarcoma.
Computed tomography and positron emission tomography scans showed no signs of metastasis, and no
other abnormal hypermetabolic lesions were detected. Wide excision with split-thickness skin graft and
a sentinel lymph node biopsy were performed. Because of positive ﬁndings in the sentinel lymph nodes,
the patient was transferred to the plastic surgery department for further radical popliteal and inguinal
lymph node dissection. The patient has received regular outpatient follow-up care in our hospital for the
past 8 months with no evidence of recurrence.
Copyright  2012, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Cutaneous clear cell sarcoma (CCS), also known as CCS of the
tendons or aponeuroses or melanoma of the soft tissues, was ﬁrst
described in 1965 by Franz Enzinger.1 This raremalignant neoplasm
accounts for only 1% of soft tissue sarcomas.2e4 Clinically, most
cases of CCS occur in adolescents and young adults. It typically
arises in the deep soft tissues of the extremities, particularly the
feet and hands, although cases have also been documented in the
penis, trunk, head, and neck.5e9 The growth pattern is indolent in
the early stages but aggressive in the late stages. The histopatho-
logical and immunohistochemical similarities between clear cell
sarcoma and malignant melanoma may lead to misdiagnosis.5,10
Further examination using conventional chromosome analysis,
ﬂuorescent in situ hybridization (FISH), or reverse transcriptase-
polymerase chain reaction (RT-PCR) may aid in its diagnosis.11
Only one case of primary clear cell sarcoma with epidermal
involvement has been reported in the literature.10 Here, we present
a case of clear cell sarcoma on the right heel with skin invasion due
to prolonged duration.ent of Dermatology, China
No. 2, Yu-Der Road, Taichung
: þ886 4 22076506.
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A 43-year-old male without a signiﬁcant medical history or any
traumatic injuries visited the outpatient clinic of the dermatology
department of our hospital because of a palpable ﬁrm mass on the
right heel that had been present for more than 30 years. The patient
recalled that a bean-sized nodule had been present since child-
hood. The nodule was ﬁrm, unmovable, and had enlarged over the
past 10 years. The lesion was biopsied 5 months prior at another
hospital; the pathology report showed hyperkeratotic tissue
accompanied by inﬂammatory cells. The biopsy wound did not heal
well, so several traditional medical treatments were tried but all
were unsuccessful. Thus, the patient came to us for further evalu-
ation and management. Upon inspection, the tumor was
45 mm  30 mmwith a linear biopsy scar in the center. There was
no erythema or melanin pigmentation. However, a yellowish-
brown discharge with tenderness and pain over the sole were
noted (Figure 1).
Under the tentative diagnosis of a hyperkeratotic or ﬁbrous
tumor with nonhealing postbiopsy wound, the patient underwent
total excision of the tumor with split-thickness skin grafting.
Pathological examination of the biopsied specimen revealed indi-
vidual to clustered, atypical, clear, melanocytic-like tumor cells that
involved the whole dermis and subcutis and projected deep into
the fascial-tendon soft tissues, approaching the junctional regionn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 On the right heel, one egg-sized (4.5  3.0 cm), ﬁrm, subcutaneous nodule
with a nonhealing ulceration surface and overlying thick hyperkeratosis. No other skin
lesions were found. No obvious melanin pigmentation was noted.
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reactive hyperkeratosis and focal parakeratosis, indistinct melanin
pigment deposition, and no obvious pagetoid spreading (Figure 2).
The tumor cells showed positive cytoplasmic staining for HMB-45
and S-100 proteins. Two tentative diagnoses were considered:
cutaneous melanoma with deep soft tissue invasion or clear cell
sarcoma with upward skin invasion (Figure 3).
A secondary, wider tumor excision was performed with popli-
teal and inguinal sentinel lymph node biopsy, which showedFigure 2 Microscopic analysis of the biopsied tumor cells. (A) Tumor cell nests involving th
staining [H&E] 5). (B) Individual to clustered atypical clear melanocytic-like tumor cells
keratosis (H&E, 100). (C) The tumor consists of nests of clear cells separated by irregular ﬁb
located nuclei with prominent nucleoli (H&E, 400).positive lymph node involvement. The primary tumor location
showed no residual lesions, and the calcaneal tuberosity of the
bone was free of any indications of metastasis. Computed tomog-
raphy and positron emission tomography scans showed no signs of
metastasis or other abnormal hypermetabolic lesions. Because
a positive sentinel lymph node was found, the patient was trans-
ferred to the plastic surgery department for further radical popli-
teal and inguinal lymph node dissection.
To conﬁrm the diagnosis, a FISH cytogenetic study was per-
formed. DNA in situ hybridization for 22q12 using the Vysis EWS
gene dual-color kit (Abbott Molecular, Des Plaines, IL, USA) showed
scattered break points at the 22q122 (EWS) gene (Figure 4). There-
fore, clear cell sarcomawas diagnosed. The patient hasmade regular
outpatient follow-up visits to our hospital during the 8 months
after diagnosis and treatment without evidence of recurrence.
Discussion
In the case of CCS with epidermal involvement, differential diag-
nosis from cutaneous malignant melanoma may be difﬁcult.11
However, the distinct clinical presentation (e.g., slow and indo-
lent growth in the early stages, very long prebiopsy duration, deep-
seated location, young age, and ﬁrm consistency) and cytogenetic
tests may help to arriving at the correct diagnosis.
In our case, the histological ﬁndings showed focal and upward
skin involvement. However, we believe that the tumor growth star-
ted deep within the site rather than as a primary cutaneous mela-
noma due to hyperkeratosis and the nonerosive surface. Because
the tumor grows slowly from deep within the site, the overlying
epidermis become hyperkeratotic under chronic stimulation,e whole dermis, subcutis, and the deep fascial-tendon soft tissue (hematoxylin & eosin
in the junctional region and papillary dermis with overlying marked reactive hyper-
rous bundles (H&E, 200). (D) Tumor cells with abundant clear cytoplasm and centrally
Figure 3 Immunohistochemical analysis of biopsied tumor cells showing (A) positive cytoplasmic staining for the S-100 protein (H&E, 200) and (B) positive cytoplasmic staining
for HMB-45 (H&E, 200).
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the junctional area, the epidermal surface would have become
erosive, as commonly seen in nodular melanoma.
Histologically, CCS is highly inﬁltrative with haphazard
arrangement into compact nests and fascicles of pale fusiform or
epithelioid cells surrounded by a ﬁne ﬁbrous framework of
tendons, fascia, and aponeuroses.2,11,12 The stroma may be barely
visible, ﬁbrotic, or hyalinized. The neoplastic cells of CCS are
polygonal to fusiform with lightly eosinophilic cytoplasm and
centrally located round-to-ovoid vesicular nuclei with prominent
basophilic nucleoli. Cellular polymorphisms and mitotic ﬁgures are
uncommon. The frequent appearance of multinucleated giant cells
may provide a valuable diagnostic clue.11
Immunohistochemically, CCS shares an identical proﬁle with
malignant melanoma and expresses S-100, HMB-45, Melan-A,
and vimentin, with or without microphthalmia transcription
factor.2,6,11,13 A recent study by Hisaoka et al showed strong S100
protein expression in 100% of cases, and expression of HMB-45,
Melan-A, and microphthalmia transcription factor in 97%, 71%
and 81% of cases, respectively.14
The pathological differential diagnosis of CCS includes malignant
melanoma, malignant peripheral nerve sheath tumor (MPNST), and
synovial sarcoma. The predominantly deep-seated location andFigure 4 Detection of EWS rearrangement by ﬂuorescence in situ hybridization (FISH) analy
(red arrow) in the 22q12 (EWS) gene. (B) High-power view. The split, single, red, and greedeep soft tissue involvement in CCS with upward tumor invasion,
mostly without direct connection to the epidermis, may distinguish
it from malignant melanoma. However, focal epidermal invasion,
as documented in one study,10 was also observed in our patient
perhaps due to long duration or the palmoplantar location. The
critical distinction between CCS and malignant melanoma depends
on the results of cytogenetic studies: the chromosomal translocation
t(12;22)(q13;q12) and EWSR1/ATF1 gene rearrangement, which is
considered pathognomonic of CCS, is found in 75% of all cases using
FISH or RT-PCR.2,10 MPNST is usually associatedwith the nerve trunk
or manifests in the settings of neuroﬁbromatosis type I, thereby
revealing myxoid stroma, hyperchromatic nuclei, brisk mitotic
activity, and negative staining for HMB-45 and Melan-A. Synovial
sarcoma is often composed of spindle cell and glandular compo-
nents that form a characteristic biphasic pattern. Besides, negative
staining for HMB-45, characteristic chromosomal translocation
t(X;18)(p11.2;q11.2), and SYT/SSX1 or SYT/SSX2 gene fusion tran-
scripts may distinguish synovial sarcoma from CCS.
The main treatment for CCS is immediate wide excision with
adequate safety margins. Chemotherapy and radiotherapy have
not been shown to provide any additional beneﬁt to the survival
rate.2,6,15 Poor prognostic factors include tumor size (5 cm),
necrosis, metastasis, and local recurrence.5,10,16,17 The mostsis. (A) In this case, the Vysis EWS gene dual-color kit revealed scattered break points
n signals correspond to the rearranged EWS allele.
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heart, brain, bone, and skin.5,12,18 Sentinel lymph node biopsy can
detect early occult regional metastasis. The 5-year survival rate
after radical resection and chemotherapy or radiotherapy has been
estimated to be about 67%, while the 10-year survival rate is about
33%.2,3,6
Early recognition and initial radical surgery are key factors that
determine a favorable outcome, while chemotherapy and radio-
therapy do not help. As shown in this case, CCS should be listed in
the differential diagnosis when the histopathological features are
similar to cutaneous melanoma in the lower extremities of young
adults, but the tumor often takes a more indolent clinical course.
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